Get the Stockscreener App
5.72
0.53%
0.03
After Hours:
5.70
-0.02
-0.35%
Annexon Inc stock is traded at $5.72, with a volume of 1.92M.
It is up +0.53% in the last 24 hours and up +4.00% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.69
Open:
$5.78
24h Volume:
1.92M
Relative Volume:
0.76
Market Cap:
$929.54M
Revenue:
-
Net Income/Loss:
$-206.69M
P/E Ratio:
-4.2198
EPS:
-1.3555
Net Cash Flow:
$-186.49M
1W Performance:
-4.67%
1M Performance:
+4.00%
6M Performance:
+90.03%
1Y Performance:
+216.02%
1-Day Range:
$5.635
$5.88
1-Week Range:
$5.62
$6.065
52-Week Range:
$1.60
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.72 | 924.67M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
ANNX Earnings History & Surprises | EPS & Revenue Results | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Annexon | DEFA14A: Others - Moomoo
Annexon | ARS: Annual Report to Security Holders - Moomoo
ANNX: Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026 - TradingView
Annexon (NASDAQ: ANNX) proxy asks approval to boost share authorization and elect directors - Stock Titan
Annexon stock rises after director purchases shares - MSN
Annexon presents four studies on Guillain-Barre syndrome disease burden and targeted therapies - Traders Union
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential - Insider Monkey
Annexon Biosciences Stock Surges 289 Percent Amid Clinical Progress - HarianBasis.co
Annexon Biosciences (ANNX) Buy Rating Retained - Insider Monkey
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Does Annexon’s 2026 “Win Year” Milestone Roadmap Reshape The Bull Case For Annexon (ANNX)? - simplywall.st
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Annexon Biosciences (ANNX) and UnitedHealth (UNH) - The Globe and Mail
Annexon (NASDAQ: ANNX) seeks vote to increase authorized shares to 500M - Stock Titan
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing - Yahoo Finance
Annexon (NASDAQ:ANNX) Trading 8.5% Higher Following Insider Buying Activity - MarketBeat
Carson buys $49k in Annexon (ANNX) stock - Investing.com
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 8,000 Shares of Stock - MarketBeat
Carson buys $49k in Annexon (ANNX) stock By Investing.com - Investing.com India
Annexon (NASDAQ: ANNX) director adds 8,000 shares in planned stock purchase - Stock Titan
EV Market: Will Annexon Inc benefit from government policyWall Street Watch & Technical Buy Zone Confirmation - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Shares Down 6.1%Here's Why - MarketBeat
Is Annexon (ANNX) Stock Undervalued Now | ANNX Q4 Earnings: Beats Estimates by $0.04PEG Ratio - Cổng thông tin điện tử tỉnh Lào Cai
Macro Review: Will Annexon Inc benefit from government policyPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Geopolitics Watch: What are the risks of holding Annexon Inc2026 Analyst Calls & Long-Term Investment Growth Plans - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Shares Up 6.6%What's Next? - MarketBeat
HC Wainwright Estimates Annexon FY2030 Earnings - MarketBeat
Annexon posts full-year 2025 financial results and portfolio updates - Traders Union
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):